¼ÒÈ­±â °ü·Ã Á¦Ç° ½ÃÀå : ±Ô¸ð, Á¡À¯À², µ¿Çâ, »ê¾÷ ºÐ¼® º¸°í¼­-µð¹ÙÀ̽ºº°, Áúº´º°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°-½ÃÀå ¿¹Ãø(2025-2034³â)
Gastrointestinal Products Market Size, Share, Trends, Industry Analysis Report: By Devices, Disease, End User, and Region - Market Forecast, 2025-2034
»óǰÄÚµå : 1625425
¸®¼­Ä¡»ç : Polaris Market Research
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 128 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,250 £Ü 5,925,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 5,250 £Ü 7,320,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ 20¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,250 £Ü 8,714,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Polaris Market ResearchÀÇ ÃֽŠÁ¶»ç¿¡ µû¸£¸é ¼ÒÈ­±â °ü·Ã Á¦Ç° ½ÃÀå ±Ô¸ð´Â 2034³â±îÁö 258¾ï 5,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­´Â ÇöÀç ½ÃÀå ¿ªÇÐÀ» »ó¼¼ÇÏ°Ô ÆÄ¾ÇÇÏ°í ¹Ì·¡ ½ÃÀå ¼ºÀå¿¡ ´ëÇÑ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

À§½Äµµ ¿ª·ùÁõ(GERD), ¿°Áõ¼º Àå Áúȯ(IBD), °ú¹Î¼º Àå ÁõÈıº(IBS) µî À§Àå ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ¼ÒÈ­±â °ü·Ã Á¦Ç° ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÏ´Â ÀϹÝÀûÀÎ Áúº´ Áß ÇϳªÀÔ´Ï´Ù. ÀÌ·¯ÇÑ Áúº´Àº ÈçÇØÁö°í Àֱ⠶§¹®¿¡ È¿°úÀûÀÎ Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖÀ¸¸ç, Á¦¾à ȸ»ç´Â Á¦Ç° ¶óÀξ÷ÀÇ Ãæ½ÇÀ» µµ¸ðÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ µå·¡±× Á¦Á¦ ¹× ¾à¹°Àü´Þ ½Ã½ºÅÛÀÇ Çõ½ÅÀº º¸´Ù È¿°úÀûÀ̰í ȯÀÚ°¡ »ç¿ëÇϱ⠽¬¿î Ä¡·á¹ýÀ» °³¹ßÇÏ¿© ÄÄÇöóÀ̾𽺸¦ Çâ»ó½Ãŵ´Ï´Ù. ¼ÒÈ­±â°èÀÇ °Ç°­¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡¿Í Á¶±â °³ÀÔÀÇ Á߿伺Àº ÀÌ·¯ÇÑ Ãß¼¼¸¦ ´õ¿í °­È­Çϰí ȯÀÚ°¡ ÀλçÀÌÆ®¿¡ À̸£´Â Ä¡·á ¿É¼ÇÀ» Àû½Ã¿¡ ¿ä±¸Çϵµ·Ï Ã˱¸Çϰí ÀÖ½À´Ï´Ù.

¿ø°Ý ÀÇ·á Ç÷§Æû, ÀüÀÚ ÀÇ·á ±â·Ï(EHR), ¸ð¹ÙÀÏ Çコ ¿ëµµ µî, ƯÈ÷ ¿ø°Ý ÀÇ·á ¹× µðÁöÅÐ Çコ ±â¼úÀ» ÅëÇÑ ÇコÄɾîÀÇ ±â¼ú ÅëÇÕÀº ¼ÒÈ­±â ÄɾîÀÇ »óȲÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ȯÀÚÀÇ ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ ¾×¼¼½º¸¦ Çâ»ó½ÃÄÑ ¿ø°Ý Áø´Ü ¹× ¼ÒÈ­±â ÁúȯÀÇ È¿°úÀûÀÎ °ü¸®¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ȯÀÚ´Â ÀÇ·á Àü¹®°¡·ÎºÎÅÍ Àû½Ã¿¡ Áø´Ü°ú Áö¼ÓÀûÀÎ Áö¿øÀ» Á÷Á¢ ¹æ¹®ÇÏÁö ¾Ê°í ¹ÞÀ» ¼ö ÀÖÀ¸¸ç, À̴ ƯÈ÷ ¿ø°ÝÁö¿¡ »ç´Â »ç¶÷µé¿¡°Ô À¯¿ëÇÕ´Ï´Ù. ¶ÇÇÑ ¸ð¹ÙÀÏ °Ç°­ ¾Û°ú °°Àº µðÁöÅÐ µµ±¸¸¦ ÅëÇØ ȯÀÚ´Â ÀÚ½ÅÀÇ Áõ»óÀ» ¸ð´ÏÅ͸µÇϰí, ½Ä½À°üÀ» ÃßÀûÇϰí, °³ÀÎÈ­µÈ Ä¡·á °èȹÀ» ¹ÞÀ» ¼ö ÀÖÀ¸¸ç, ´õ ³ªÀº °Ç°­ °á°ú¸¦ ÃËÁøÇÒ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ·¯ÇÑ º¯È­´Â ȯÀÚÀÇ ÆíÀǼºÀ» Çâ»ó½Ã۰í À§Àå °Ç°­ °ü¸®¿¡ ´ëÇÑ Àû±ØÀûÀÎ Á¢±ÙÀ» ÃËÁøÇÏ¸ç ±Ã±ØÀûÀ¸·Î ¸¸Á·µµ¿Í ÄÄÇöóÀ̾𽺠Çâ»ó¿¡ ±â¿©ÇÕ´Ï´Ù.

¼ÒÈ­±â °ü·Ã Á¦Ç° ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

Áúº´º°·Î, 2024³â¿¡´Â À§½Äµµ ¿ª·ùÁõ(GERD)ÀÌ ±¤¹üÀ§ÇÑ À¯º´·ü°ú »çȸÀû ÀÎÁö Áõ°¡·Î ¼¼°è ¼ÒÈ­±â °ü·Ã Á¦Ç° ½ÃÀåÀÇ ÁÖ¿ä ºÎ¹®À¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù.

¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)(ASCs) ºÐ¾ß´Â ¿Ü·¡ ¼ö¼ú¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁü¿¡ µû¶ó ¼ÒÈ­±â °ü·Ã Á¦Ç° ½ÃÀå¿¡¼­ ±Þ¼ºÀåÇϰí ÀÖ½À´Ï´Ù.

2024³â ºÏ¹Ì´Â À§½Äµµ ¿ª·ùÁõ(GERD)°ú ¿°Áõ¼º Àå Áúȯ(IBD) µî ¼ÒÈ­±â ÁúȯÀÇ À¯ÇàÀÌ ÁÖÀÎÀ¸·Î ¼ÒÈ­±â °ü·Ã Á¦Ç° ½ÃÀåÀ» ¼±µµÇß½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀº °Ç°­ °ü¸® ÁöÃâ Áõ°¡, À§Àå °Ç°­¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡, »ýȰ ½À°ü°ú °ü·ÃµÈ ¹®Á¦¸¦ ´Ù·ç´Â Àα¸ Áõ°¡ µîÀ» ¹è°æÀ¸·Î ¿¹Ãø ±â°£ µ¿¾È °¡Àå ºü¸£°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¼¼°è ÁÖ¿ä ½ÃÀå ÁøÃâ ±â¾÷À¸·Î´Â Abbott Laboratories; Johnson & Johnson; Pfizer Inc.; Bayer AG; Astellas Pharma Inc.; Takeda Pharmaceutical Company; Novartis International AG; GSK(GlaxoSmithKline); Mylan NV; Dr.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå Á¶»ç ¹æ¹ý

Á¦4Àå ¼¼°èÀÇ ¼ÒÈ­±â °ü·Ã Á¦Ç° ½ÃÀå ÀλçÀÌÆ®

Á¦5Àå ¼¼°èÀÇ ¼ÒÈ­±â °ü·Ã Á¦Ç° ½ÃÀå : µð¹ÙÀ̽ºº°

Á¦6Àå ¼¼°èÀÇ ¼ÒÈ­±â °ü·Ã Á¦Ç° ½ÃÀå : Áúȯº°

Á¦7Àå ¼¼°èÀÇ ¼ÒÈ­±â °ü·Ã Á¦Ç° ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦8Àå ¼¼°èÀÇ ¼ÒÈ­±â °ü·Ã Á¦Ç° ½ÃÀå : Áö¿ªº°

Á¦9Àå °æÀï ±¸µµ

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The gastrointestinal products market size is expected to reach USD 25.85 billion by 2034, according to a new study by Polaris Market Research. The report "Gastrointestinal Products Market Size, Share, Trends, Industry Analysis Report: By Devices, Disease, End User (Hospitals, Ambulatory Centers and Independent Diagnostic Centers, Clinics, Other End Users), and Region (North America, Europe, Asia Pacific, Latin America, and Middle East & Africa); Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rising prevalence of gastrointestinal disorders, such as gastroesophageal reflux disease (GERD), inflammatory bowel disease (IBD), and irritable bowel syndrome (IBS), are among the prevailing diseases driving the gastrointestinal products market growth. Since these conditions have become more common, there is a greater demand for effective treatments, prompting pharmaceutical companies to enhance their product offerings. Additionally, innovations in drug formulations and delivery systems have led to the development of therapies that are more effective and easier for patients to use, thereby improving compliance. This growing awareness of digestive health and the importance of early intervention further reinforces this trend, encouraging patients to seek timely treatment options led to insights.

Technological integration in healthcare, such as telemedicine platforms, electronic health records (EHRs), and mobile health applications, particularly through telemedicine and digital health technologies, is transforming the landscape of gastrointestinal care. These innovations enhance patient access to medical services, enabling remote consultations and effective management of gastrointestinal disorders. Patients are now able to receive timely diagnoses and ongoing support from healthcare professionals without the need for in-person visits, which is especially beneficial for those living in remote areas. Additionally, digital tools such as mobile health apps allow patients to monitor their symptoms, track dietary habits, and receive personalized treatment plans, promoting better health outcomes. Therefore, this shift has improved patient convenience, promoting a proactive approach to gastrointestinal health management and ultimately contributing to increased satisfaction and compliance.

Gastrointestinal Products Market Report Highlights

In terms of disease, in 2024, gastroesophageal reflux disease (GERD) has emerged as the leading segment in the global gastrointestinal products market due to its widespread prevalence and growing public awareness.

The ambulatory surgical centers (ASCs) segment is witnessing rapid growth in the gastrointestinal products market, driven by an increasing preference for outpatient procedures.

In 2024, North America led the gastrointestinal products market, largely due to the prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and inflammatory bowel disease (IBD).

Asia Pacific is projected to experience the fastest growth during the forecast period, driven by increasing healthcare spending, heightened awareness of gastrointestinal health, and a rising population grappling with lifestyle-related issues.

A few global key market players include Abbott Laboratories; Johnson & Johnson; Pfizer Inc.; Bayer AG; Astellas Pharma Inc.; Takeda Pharmaceutical Company; Novartis International AG; GSK (GlaxoSmithKline); Mylan N.V.; Santen Pharmaceutical Co., Ltd.; Dr. Reddy's Laboratories Ltd.

Polaris Market Research has segmented the gastrointestinal products market report on the basis of devices, disease, end user, and region:

By Devices Outlook (Revenue, USD Billion, 2020-2034)

By Disease Outlook (Revenue, USD Billion, 2020-2034)

By End User Outlook (Revenue, USD Billion, 2020-2034)

By Regional Outlook (Revenue, USD Billion, 2020-2034)

Table of Contents

1. Introduction

2. Executive Summary

3. Research Methodology

4. Global Gastrointestinal Products Market Insights

5. Global Gastrointestinal Products Market, by Devices

6. Global Gastrointestinal Products Market, by Disease

7. Global Gastrointestinal Products Market, by End User

8. Global Gastrointestinal Products Market, by Geography

9. Competitive Landscape

10. Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â